Alaunos Therapeutics, Inc. (TCRT) Earnings History
Annual and quarterly earnings data from 2001 to 2024
Loading earnings history...
TCRT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
TCRT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -48120.0% | -46790.0% |
| 2023 | -95960.0% | -685340.0% | -702800.0% |
| 2022 | 100.0% | -1201.4% | -1291.2% |
| 2021 | 100.0% | -19484.7% | -19786.7% |
| 2020 | - | - | - |
Download Data
Export TCRT earnings history in CSV or JSON format
Free sign-in required to download data
Alaunos Therapeutics, Inc. (TCRT) Earnings Overview
As of May 8, 2026, Alaunos Therapeutics, Inc. (TCRT) reported trailing twelve-month net income of -$4M, reflecting +86.7% year-over-year growth. The company earned $-1.84 per diluted share over the past four quarters, with a net profit margin of -46790.0%.
Looking at the long-term picture, TCRT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$35,842 in fiscal 2003.
Alaunos Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IOVA (-$354M net income, -148.4% margin), FATE (-$136M net income, -2051.1% margin), TCRX (-$124M net income, -1256.8% margin), TCRT has room to improve margins relative to the peer group. Compare TCRT vs IOVA →
TCRT Earnings vs Peers
Earnings metrics vs comparable public companies
TCRT Historical Earnings Data (2001–2024)
24 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$5M | +86.7% | -$5M | $-2.92 | -46790.0% | -48120.0% |
| 2023 | -$35M | +6.9% | -$34M | $-21.97 | -702800.0% | -685340.0% |
| 2022 | -$38M | +52.1% | -$35M | $-25.97 | -1291.2% | -1201.4% |
| 2021 | -$79M | +1.5% | -$78M | $-53.80 | -19786.7% | -19484.7% |
| 2020 | -$80M | +32.1% | -$80M | $-56.42 | - | - |
| 2019 | -$118M | -121.8% | -$58M | $-158.90 | - | - |
| 2018 | -$53M | +2.2% | -$54M | $-55.44 | -36381.5% | -36921.9% |
| 2017 | -$54M | +67.1% | -$53M | $-59.50 | -850.3% | -837.3% |
| 2016 | -$165M | -37.6% | -$165M | $-190.15 | -2409.2% | -2409.4% |
| 2015 | -$120M | -277.9% | -$120M | $-143.63 | -2772.1% | -2772.4% |
See TCRT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TCRT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TCRT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTCRT — Frequently Asked Questions
Quick answers to the most common questions about buying TCRT stock.
Is TCRT growing earnings?
TCRT EPS is $-1.84, with earnings growth accelerating to +86.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-4M.
What are TCRT's profit margins?
Alaunos Therapeutics, Inc. net margin is -46790.0%, with operating margin at -48120.0%. Below-average margins reflect competitive or cost pressures.
How consistent are TCRT's earnings?
TCRT earnings data spans 2001-2024. The accelerating earnings trend is +86.7% YoY. Historical data enables comparison across business cycles.